Timing and optimized acquisition parameters for the whole-body imaging of 177Lu-EDTMP toward performing bone pain palliation treatment

被引:9
|
作者
Liu, Congjin [1 ]
Brasic, James Robert [3 ]
Liu, Xingdang [1 ]
Li, Hongyu [2 ]
Xiang, Xueqin [2 ]
Luo, Zhifu [2 ]
Wang, Yuankai [1 ]
Kuai, Dayu [1 ]
Zhang, Guangming [1 ]
Zaknun, John J. [4 ]
机构
[1] Fudan Univ, Huashan Hosp, Dept Nucl Med, Shanghai 200040, Peoples R China
[2] China Inst Atom Energy, Dept Isotope, Beijing, Peoples R China
[3] Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Div Nucl Med, Sch Med, Baltimore, MD USA
[4] IAEA, Nucl Med Sect, Div Human Hlth, A-1400 Vienna, Austria
关键词
bone seeking radiopharmaceuticals; camera acquisition settings; lutetium-177-EDTMP; radionuclide therapy; whole-body imaging; POTENTIAL AGENTS; THERAPY; RADIOPHARMACEUTICALS; SM-153-EDTMP; DOSIMETRY;
D O I
10.1097/MNM.0b013e32834d3c13
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives Lutetium-177-labeled ethylenediamine-N,N,N',N'-tetrakis (methylene phosphonic acid) (Lu-177-EDTMP), a beta-emitting bone-seeking therapeutic radiopharmaceutical being assessed as an agent for palliation of bone pain, can emit suitable gamma-photons for scintigraphy. This investigation sought to characterize its optimal conditions for whole-body gamma camera imaging in patients. Materials and methods Eleven patients with bone metastases underwent whole-body bone scanning using both Tc-99m-methyl-diphosphonate (Tc-99m-MDP) and Lu-177-EDTMP (29.4 +/- 12.5MBq/kg BW) utilizing a dual-head camera. For lutetium-177 imaging, two types of collimators, low-energy high-resolution (LEHR) and medium-energy general-purpose (MEGP), and two different peak energies of 113 and 208 keV were used. Results The femur-to-muscle uptake ratio (F/M) of Tc-99m-MDP was 2.69 +/- 1.06. For Lu-177-EDTMP, the significantly highest F/Ms were found at 24 h (12.59 +/- 5.73) and 48 h (12.54 +/- 5.23) by applying MEGP collimators and collecting the 208 keV photons. In all the combinations of collimator and peak energy, the F/Ms at 24 and 48 h are significantly higher than those at 1 h, except the combination of LEHR collimator and 208 keV peak energy. Lesion-to-normal bone uptake ratios of the Tc-99m-MDP bone scan and images at the 24 and the 48-h phases of Lu-177-EDTMP were analyzed. MEGP and 208 keV had significantly higher values in lesion-to-normal bone uptake ratios. The combination of LEHR and 208 keV provided the poorest images. Conclusion Lu-177-EDTMP can provide fine whole-body images with the best results when applying mediumenergy collimation and collecting the 208 keV energy photons and alternatively by collecting both 208 and 113 keV photons for higher count statistics. The most appropriate time point for imaging is around 24 h after injection. Nucl Med Commun 33:90-96 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:90 / 96
页数:7
相关论文
共 21 条
  • [1] Whole-body imaging study with 177Lu-EDTMP in patients: As a new therapeutical agent of bone metastasis
    Liu, Congjin
    Liu, Xingdang
    Li, Hongyu
    Luo, Zhifu
    Zhang, Guangming
    Wang, Yuankai
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [2] 177Lu-EDTMP for Metastatic Bone Pain Palliation: A Systematic Review and Meta-analysis
    Askari, Emran
    Harsini, Sara
    Vahidfar, Nasim
    Divband, Ghasemali
    Sadeghi, Ramin
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2021, 36 (05) : 383 - 390
  • [3] Preparation and biological assessment of 177Lu-BPAMD as a high potential agent for bone pain palliation therapy: comparison with 177Lu-EDTMP
    Hassan Yousefnia
    Samaneh Zolghadri
    Hamid Reza Sadeghi
    Mojdeh Naderi
    Amir Reza Jalilian
    Saeed Shanehsazzadeh
    Journal of Radioanalytical and Nuclear Chemistry, 2016, 307 : 1243 - 1251
  • [4] Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent
    Mathe, Domokos
    Balogh, Lajos
    Polyak, Andras
    Kiraly, Reka
    Marian, Terez
    Pawlak, Dariusz
    Zaknun, John J.
    Pillai, Maroor R. A.
    Janoki, Gyozo A.
    NUCLEAR MEDICINE AND BIOLOGY, 2010, 37 (02) : 215 - 226
  • [5] Production, Quality Control and Pharmacokinetic Studies of 177Lu-EDTMP for Human Bone Pain Palliation Therapy Trials
    Bahrami-Samani, Ali
    Anvari, Akbar
    Jalilian, Amir Reza
    Shirvani-Arani, Simindokht
    Yousefnia, Hassan
    Aghamiri, Mahmoud Reza
    Ghannadi-Maragheh, Mohammad
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2012, 11 (01): : 137 - 144
  • [6] Preparation and biological assessment of 177Lu-BPAMD as a high potential agent for bone pain palliation therapy: comparison with 177Lu-EDTMP
    Yousefnia, Hassan
    Zolghadri, Samaneh
    Sadeghi, Hamid Reza
    Naderi, Mojdeh
    Jalilian, Amir Reza
    Shanehsazzadeh, Saeed
    JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, 2016, 307 (02) : 1243 - 1251
  • [7] 177Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study
    Krishan Kant Agarwal
    Suhas Singla
    Geetanjali Arora
    Chandrasekhar Bal
    European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42 : 79 - 88
  • [8] 177Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study
    Agarwal, Krishan Kant
    Singla, Suhas
    Arora, Geetanjali
    Bal, Chandrasekhar
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (01) : 79 - 88
  • [9] 177Lu-EDTMP for bone pain palliation in patients with bone metastases: Pharmacokinetics and toxicity evaluation using dose escalation schedule
    Saeed, Shabana
    Zaknun, John
    Jameel, Ghazal
    Ahmed, Naseer
    Irfan, Javaid
    Fatima, Shazia
    Qureshy, Ahmad
    Afzal, Muhammad Shahzad
    Mariani, Giuliano
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [10] Comparative therapeutic efficacy of 177Lu-EDTMP and 153Sm-EDTMP in bone pain palliation in cancer patients with multiple skeletal metastases
    Singh, Baljinder
    Prashar, Sarika
    Koul, Ashwani
    Mittal, Bhagwant
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57